Ongoing clinical trials of VEGF-targeted therapy in UC
Drugs | Targets | Combinations | Conditions | Phase | NCT |
---|---|---|---|---|---|
Bevacizumab | VEGF | MK-7684A | UC | II | NCT05007106 |
Bevacizumab | VEGF | Dasatinib | Met/Adv UC | I | NCT04164069 |
Lenvatinib | VEGFR1–3 | GI-101 | Met/Adv UC | I/II | NCT04977453 |
Lenvatinib | VEGFR1–3 | MK-7684A | UC | II | NCT05007106 |
Ramucirumab | VEGFR2 | TRK-950 | UC | I | NCT03872947 |
VEGF: vascular endothelial growth factor; UC: urothelial carcinoma; VEGFR1–3: vascular endothelial growth factor receptor 1–3; Adv: advanced; Met: metastatic; MK-7684A: the combination of vibostolimab and pembrolizumab; GI: SIM0323
SS, LZ, and KL contributed equally to: Writing—original draft, Writing—review & editing. ML, JZ, DJ, DW, ZS, and PX: Investigation, Writing—review & editing. JY and ZZ: Conceptualization, Writing—review & editing, Supervision. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
This study was supported by the Shaanxi Province Key Industry Chain Project [2022ZDLSF05-14]. The funder played no role in the study design, data collection and analysis, decision to publish, or in the preparation of the manuscript.
© The Author(s) 2024.